摘要:
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
摘要:
A method of producing polyhydroxyalkanoate (PHA) copolymers comprising both short-chain-length (scl) and medium-chain-length (mcl) subunits, wherein some of the mcl subunits bear reactive vinyl groups, is provided. The method comprises providing cells comprising (i) a PHA synthase (phaC) gene encoding a particular class I poly(3-hydroxyalkanoate) polymerase, and (ii) a phaJ gene encoding a particular (R)-specific enoyl-CoA hydratase, and cultivating said cells in a growth medium comprising an alkenoic acid. In one example, cells grown in the presence of a mixture of decanoic acid and undecen-10-enoic acid yielded a copolymer comprising units of 3-hydroxybutyrate (94.73 mol %), 3-hydroxyhexanoate (1.51 mol %), 3-hydroxyoctanoate (2.33 mol %), 3-hydroxydecanoate (0.69 mol %) and 3-hydroxyhept-6-enoate (0.73 mol %). The presence of acrylic acid as a 13-oxidation inhibitor in the growth medium led to an increase in both the mcl-PHA subunit content and vinyl subunit content. For example, a copolymer containing about 1.2 mol % 3-hydroxyhept-6-enoate and about 0.5 mol % 3-hydroxynon-8-enoate was obtained at a concentration of 40 mM acrylic acid. PHA accumulation of up to 57.2% (w/w of cell dry weight) are reported. The scl-mcl PHAs with subunits bearing reactive vinyl groups are expected to be useful in a variety of applications, for instance for covalently linking bioactive molecules.
摘要:
Described is a method for the production of 3-buten-2-one comprising the enzymatic conversion of 4-hydroxy-2-butanone into 3-buten-2-one by making use of an enzyme catalyzing 4-hydroxy-2-butanone dehydration, wherein said enzyme catalyzing 4-hydroxy-2-butanone dehydration is (a) a 3-hydroxypropiony-CoA dehydratase (EC 4.2.1.116), (b) a 3-hydroxybutyryl-CoA dehydratase (EC 4.2.1.55), (c) an enoyl-CoA hydratase (EC 4.2.1.17), (d) a 3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.59), (e) a crotonyl-[acyl-carrier-protein] hydratase (EC 4.2.1.58), (f) a 3-hydroxydecanoyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.60), (g) a 3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.61), (h) a long-chain-enoyl-CoA hydratase (EC 4.2.1.74), or (i) a 3-methylglutaconyl-CoA hydratase (EC 4.2.1.18). The produced 3-buten-2-one can be further converted into 3-buten-2-ol and finally into 1,3-butadiene.
摘要:
Described is a method for the production of 3-buten-2-one comprising the enzymatic conversion of 4-hydroxy-2-butanone into 3-buten-2-one by making use of an enzyme catalyzing 4-hydroxy-2-butanone dehydration, wherein said enzyme catalyzing 4-hydroxy-2-butanone dehydration is (a) a 3-hydroxypropiony-CoA dehydratase (EC 4.2.1.116), (b) a 3-hydroxybutyryl-CoA dehydratase (EC 4.2.1.55), (c) an enoyl-CoA hydratase (EC 4.2.1.17), (d) a 3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.59), (e) a crotonyl-[acyl-carrier-protein] hydratase (EC 4.2.1.58), (f) a 3-hydroxydecanoyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.60), (g) a 3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.61), (h) a long-chain-enoyl-CoA hydratase (EC 4.2.1.74), or (i) a 3-methylglutaconyl-CoA hydratase (EC 4.2.1.18). The produced 3-buten-2-one can be further converted into 3-buten-2-ol and finally into 1,3-butadiene.
摘要:
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
摘要:
The present invention relates to the field of prevention and/or treatment of metabolic disorders such as obesity, metabolic syndrome, type-2 diabetes, dyslipidemia and insulin resistance,
摘要:
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
摘要:
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
摘要:
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
摘要:
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.